Lupin announced yesterday the completion of the acquisition of a portfolio of brands from Anglo-French Drugs and Industries and its associates.
The acquisition will strengthen Lupin’s India formulation business by adding a fast-growing portfolio of vitamins, minerals, supplements and neurological products. The acquisition of the Anglo-French Drugs and Industries’ brands takes Lupin further in shaping its portfolio to emerge as a leading pharma company in India, Lupin said in a statement.
“The portfolio sold to Lupin was birthed by Anglo-French, and now, through this divestiture, we are confident that these brands will scale to a significant size and have a large impact on the health and well-being of the Indian population…..,” said Abhay Kanoria, Chairman and MD, Anglo-French Drugs and Industries, in the statement.
Shailesh Gadre, Founder, GCV Life, was the exclusive adviser for the transaction, the statement concluded.